Business Update
Viropro emphasizes commitment to increase its visibility
Published in AIDS Weekly, August 7th, 2006
The recent reinforcement of Viropro's management team will allow the company to focus and to set short and mid-term priorities to maximize shareholders' value.
On June 15, 2006, the company announced the signature of a binding Memorandum of Understanding (MOU) with Biochallenge, a Tunisia-based, privately held pharmaceutical company, for the development and the production of several therapeutic proteins, with potential revenues estimated at US$27 million. The final contractual agreement is expected in the following months.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-08-07)
More Articles from AIDS Weekly
- HIV-2 Infection
Maintenance of HIV-specific CD4 cells delay disease progression in HIV-2 infection - HIV/AIDS & Chlamydial Proctitis
Chlamydial proctitis is a re-emerging sexually transmitted disease in HIV/AIDS - HIV/AIDS Drug Screening
Protease inhibitors identified by chemical taxonomy-based search engine - HIV/AIDS Epidemiology
Fifteen to 30% of HIV infections in U.S. occur in individuals younger than 25 years of age - HIV/AIDS Risk Factors
HIV detected in blood residue from syringes shared among drug users in Dar es Salaam - Adverse Drug Reaction
Severe liver disease is associated with prolonged antiretroviral drug exposure - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
